% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • ttango2200 ttango2200 Feb 29, 2012 7:49 PM Flag

    Rejection priced in or not? Prediction for AM?

    So was ARMN's patent rejection priced in? And what are your predictions for tomorrow? All replies appreciated--thanks!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • For this rejection? No. If anything what was built into the price partially was the expected issuance of the '889 patent. And what happened today shouldn't damper those expectations!

      I think today's drop was a knee jerk reaction by a lot uninformed investors not understanding the patent process.

      We only know that not "all" of what Amarin was seeking for allowance was accepted. And this is hardly surprising. We'll have to wait for the PTO to publish the details.

      Parts of the 889 patent were probably allowed and if that's the case then it's just a matter of time before the 889 patent gets issued.

      Amarin will then reapply with the accepted processes of the patent and then the PTO finally issues the patent.

      • 2 Replies to venus537
      • This will be down a buck tomorrow. Happens every time this BS comes to the surface. Shorts will use this several more times

      • bigcobramcjingleballs bigcobramcjingleballs Feb 29, 2012 11:45 PM Flag

        AMRN is pursuing 16 Patents.... FYI,

        Amarin's plan consists of seeking robust patent protection and regulatory exclusivity, maintaining trade secrets and taking advantage of manufacturing barriers to entry, with the goal of protecting the commercial potential of AMR101 until at least 2030. Amarin had previously disclosed that it is prosecuting a total 16 U.S. patent applications across 11 patent families. The actual number of patent applications and patent families has since grown due to the splitting of previously filed applications among multiple continuations and the filing of new applications seeking to cover what the company believes is additional patentable subject matter based on AMR101 clinical results."

    • I agree that the patent issue is an important one for the longer term success of the drug. But there's no way that this stock is not going to be a lot higher than this on approval. And there's still plenty of time for positive news on the patent front before the approval in July. I say it's oversold and will bounce nicely tomorrow. If a market correction gives me a still lower price, so much the better!

    • Not priced in.

2.40+0.01(+0.42%)12:54 PMEDT